Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 10/20 | 0.52 |
| ▸ | KLK7 | P49862 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12890921 | 0.93 | KLK7 (0.49) | FKBP1AKLK7CTSLPARP1F2 | |
| SCHEMBL842288 | 0.93 | KLK7 (0.49) | FKBP1AKLK7CTSLPARP1F2 | |
| SCHEMBL1300740 | 0.93 | KLK7 (0.49) | FKBP1AKLK7CTSLPARP1F2 | |
| SCHEMBL31390581 | 0.87 | FKBP1A (0.48) | FKBP1AKLK7CTSLPARP1F2 | |
| SCHEMBL9951077 | 0.84 | KLK7 (0.47) | FKBP1AKLK7CYP2C19PARP1F2 | |
| SCHEMBL7420306 | 0.84 | KLK7 (0.47) | FKBP1AKLK7CYP2C19PARP1F2 | |
| SCHEMBL2924800 | 0.83 | FKBP1A (0.45) | FKBP1AKLK7CTSLF2HPGD | |
| SCHEMBL13601193 | 0.82 | FKBP1A (0.47) | FKBP1AKLK7CTSLF2HPGD | |
| SCHEMBL16584576 | 0.82 | FKBP1A (0.41) | FKBP1AKLK7HPGD | |
| SCHEMBL15281912 | 0.82 | FKBP1A (0.41) | FKBP1AKLK7HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | REN, AGTR1, AGTR2 | FKBP1A 2153/4885KLK7 2495/4885CYP3A4 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.